Cephalosporin compound

Abstract

The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., Pseudomonas aeruginosa ) and Gram-positive (e.g., methicillin-resistant Staphylococcus aureus ) bacteria. Methods of manufacturing the compound of formula (I), and uses of the compound in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

1 - 3 . (canceled) 
     
     
         4 . A method for treating an infectious disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising the compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         5 - 9 . (canceled) 
     
     
         10 . The method of  claim 4 , wherein the infectious diseases is caused by a Gram-negative bacteria. 
     
     
         11 . The method of  claim 10 , wherein the Gram-negative bacteria is  Pseudomonas aeruginosa.   
     
     
         12 . The method of  claim 4 , wherein the subject has hospital acquired pneumonia (HAP). 
     
     
         13 . The method of  claim 4 , wherein the subject has ventilator acquired pneumonia (VAP). 
     
     
         14 . A method of treating an infection caused by  Pseudomonas aeruginosa,  comprising parenterally administering to a patient in need thereof a pharmaceutical composition comprising a carrier and a therapeutically effective amount of a compound of Formula (I): 
       
         
           
           
               
               
           
         
         a physiologically hydrolyzable ester thereof, a solvate thereof, or a pharmacologically acceptable salt thereof. 
       
     
     
         15 . The method of  claim 14 , wherein the therapeutically effective amount is effective against a  Pseudomonas aeruginosa  bacteria with a minimum inhibitory concentration (MIC) of not more than about 4 micrograms/mL. 
     
     
         16 . The method of  claim 15 , wherein the minimum inhibitory concentration (MIC) is not more than about 2 micrograms/mL. 
     
     
         17 . The method of  claim 15 , wherein the minimum inhibitory concentration (MIC) is not more than about 1 microgram/mL. 
     
     
         18 . The method of  claim 15 , wherein the subject has hospital acquired pneumonia (HAP). 
     
     
         19 . The method of  claim 15 , wherein the subject has ventilator acquired pneumonia (VAP). 
     
     
         20 . A method of making the compound of Formula (I) comprising the step of reacting intermediate compound 6: 
       
         
           
           
               
               
           
         
         with an intermediate compound 12: 
       
       
         
           
           
               
               
           
         
         to produce the compound of Formula (I):